United States: Wilmerhale Represents Fulcrum Therapeutics In Series A Financing From GV
Last Updated: May 17 2017

Fulcrum Therapeutics, a company focused on discovering and developing small molecule therapies to unlock gene control and treat serious genetic diseases, announced that it has secured additional Series A funding from GV (formerly Google Ventures) to support the continued advancement of its lead programs in Fragile X syndrome and Fascioscapularhumeral muscular dystrophy.

The WilmerHale team representing Fulcrum Therapeutics includes Lia Der Marderosian, Stephanie Singer and Byron Crowe.

Read Fulcrum Therapeutics' press release for more information.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

 
Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Press Releases from this Firm
Recent Content from this Firm
By Raya Treiser, Rob Lehman
By Gary Born
By Leila Gaafar
By Timothy Silva, Seth Davis
By Christopher Babbitt, Jonathan Bressler, Claire Chung
By WilmerHale
By Jonathan Yarowsky, Perry A. Lange, Hartmut Schneider, Leon Greenfield, D. Reed Freeman, Jr., Heather Zachary
By Jay Holtmeier, Erin Sloane
By Geoffroy Barthet, Nicole Callan, Cormac O'Daly, Hartmut Schneider
By WilmerHale
Tools
Print
Font Size:
Translation
Channels